AC-0676
- Generic Name
- AC-0676
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05780034
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath